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Abstract
Liver fibrosis is a pathological scarring response to chronic hepatocellular injury and hepatic stellate cells (HSCs) are key players
in this process. PNPLA3 I148M is a common variant robustly associated with liver fibrosis but the mechanisms underlying this
association are unknown. We aimed to examine a) the effect of fibrogenic and proliferative stimuli on PNPLA3 levels in HSCs
and b) the role of wild type and mutant PNPLA3 overexpression on markers of HSC activation and fibrosis.
Here, we show that PNPLA3 is upregulated by the fibrogenic cytokine transforming growth factor-beta (TGF-b), but not by
platelet-derived growth factor (PDGF), and is involved in the TGF-b-induced reduction in lipid droplets in primary human
HSCs. Furthermore, we show that retinol release from human HSCs ex vivo is lower in cells with the loss-of-function PNPLA3
148M compared with 148I wild type protein. Stable overexpression of PNPLA3 148I wild type, but not 148M mutant, in human
HSCs (LX-2 cells) induces a reduction in the secretion of matrix metallopeptidase 2 (MMP2), tissue inhibitor of metalloprotei-
nase 1 and 2 (TIMP1 and TIMP2), which is mediated by retinoid metabolism. In conclusion, we show a role for PNPLA3 in HSC
activation in response to fibrogenic stimuli. Moreover, we provide evidence to indicate that PNPLA3-mediated retinol release
may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling.
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Introduction
Liver fibrosis is a pathological scarring response to chronic he-
patocellular injury in individuals with chronic liver disease.
Liver fibrosis results from an imbalance between the production
and degradation of extracellular matrix and is potentially re-
versible if the liver injury is eliminated (1). Conversely, if the
liver injury persists, liver fibrosis can progress to cirrhosis,
which is associated with nodule formation and the develop-
ment of sinusoidal portal hypertension (2). However, there is a
large inter-individual heterogeneity in the susceptibility to de-
velop clinically significant fibrosis.
Hepatic stellate cells (HSCs) play a key role in the develop-
ment of liver fibrosis (3). In physiological conditions, HSCs are
the main reservoir of the body’s retinoids (vitamin A), which are
stored in their lipid droplets (4). After liver damage, HSCs lose
their retinol content and transdifferentiate into activated myofi-
broblasts. Active HSCs produce the collagen fibres, the scaffold
of the extracellular matrix, and inflammatory and fibrogenic
factors involved in matrix remodelling (5). Several proteins
modulate hepatic fibrogenesis by acting on HSCs (5,6).
Transforming growth factor-beta (TGF-b) is the major fibrogenic
cytokine in liver disease and it is increased in animal models of
liver fibrosis and in patients with chronic liver disease (7,8).
PDGF is the most potent mitogen for HSCs and is upregulated in
the fibrotic liver (9).
Patatin-like phospholipase domain-containing 3 (PNPLA3,
also called adiponutrin, ADPN) is a membrane-bound protein
with predominant lipase activity (10,11). We have shown that
PNPLA3 also has retinyl-esterase activity and is highly ex-
pressed in human HSCs, where it is involved in retinol me-
tabolism (12). In particular, PNPLA3 expression in HSCs is
regulated by retinol availability and it plays an important role
in lipid droplet remodelling, promoting the extracellular re-
lease of retinol (12). A naturally occurring sequence variation
(rs738409) resulting in an isoleucine (I) to methionine (M) sub-
stitution at position 148 (I148M) (13) of the protein is the most
robustly replicated genetic variant associated with liver dis-
ease (14), hepatic fat accumulation (15) and progression to fi-
brosis and chronic liver disease (16–19). Epidemiological
evidence suggests that the impact of the I148M mutation on
liver fibrosis progression may be independent of the predispo-
sition to hepatic fat accumulation (16,20). However, the mech-
anism underlying the direct effect on the progression to liver
fibrosis still remains obscure.
In this study, we examined the effect of the PNPLA3 148I
wild type and the 148M mutant protein on HSC activation and
the acquisition of fibrogenic phenotype. We found that PNPLA3
is upregulated by TGF-b and that overexpression of the mutant
protein results in a specific signature of proteins involved in ex-
tracellular matrix remodelling.
Results
TGF-b reduces intracellular retinyl ester content by
PNPLA3 upregulation in pHSCs
To examine if TGF-b regulates PNPLA3 synthesis, we incubated
primary HSCs with TGF-b (10 ng/ml) and examined PNPLA3 pro-
tein levels at different time points. We found that PNPLA3 was
upregulated by this cytokine (Fig. 1A). Next we examined
whether PDGF, a potent inducer of proliferation, influences
PNPLA3 synthesis. We did not find any differences in PNPLA3
synthesis after incubation with 10 ng/ml PDGF (Fig. 1B).
Next we examined whether incubation with TGF-b induces a
reduction in intracellular neutral lipid content. Primary HSCs
were incubated in medium containing retinol (10 mM) and pal-
mitic acid (100 mM) for 24 h; after this time point, the medium
was changed and cells were incubated with and without TGF-b
(10 ng/ml) in the absence of retinol and palmitic acid for up to
24 h (Fig. 2A). We observed a faster reduction in the intracellular
lipid content in cells exposed to TGF-b compared to no exposure
to TGF-b (Fig. 2B). In contrast, we did not observe any changes in
the intracellular lipid droplet content in response to PDGF 10 ng/
ml (Supplementary Material, Fig. S1).
To test whether PNPLA3 was responsible for the reduction
in intracellular lipid content after TGF-b incubation, we tested
whether the reduction in intracellular lipid content induced
by TGF-b was influenced by PNPLA3 knockdown by siRNA
(Fig. 2A–C). RNA interference downregulated PNPLA3 expression
by 3-fold (Fig. 2C). Importantly, PNPLA3 downregulation pre-
vented the TGF-b-induced reduction in intracellular lipid con-
tent (Fig. 2A and B).
Generation and characterization of a stable cell line
overexpressing PNPLA3 148I wild type and
148Mmutant
To examine the role of PNPLA3 148I wild type and its 148M
mutant in the secretion of proteins involved in fibrogenesis,
we generated and characterized a LX-2 cell line stably overex-
pressing the human PNPLA3 wild type and mutant protein
(Fig. 3A–C). In agreement with previous results of acute overex-
pression of PNPLA3 (12), we observed a reduction in the intracel-
lular lipid content of LX-2 cells overexpressing the wild type but
not the mutant protein after retinol and palmitic acid incuba-
tion for 48 h (Fig. 3A and B), suggesting that only the wild type
protein was able to reduce the intracellular lipid content. To
confirm the robustness of our model, we examined the intracel-
lular lipid content in cells after: a) retinol and palmitic acid incu-
bation for 48 h followed by retinol depletion in retinol free
medium for 24 h (Supplementary Material, Fig. S2); b) retinol
and palmitic acid incubation for 24 h (Supplementary Material,
Fig. S3A); c) retinol and palmitic acid incubation for 24 h fol-
lowed by retinol depletion in the retinol-free medium for 12 h
(Supplementary Material, Fig. S3B); and d) retinol and palmitic
acid incubation for 24 h followed by retinol depletion in the reti-
nol-free medium for 24 h (Supplementary Material, Fig. S3C).
Consistently, we observed lower intracellular lipid droplet con-
tent in cells overexpressing the wild type but not the mutant
protein under all the tested conditions.
PNPLA3 148Mmutant induces retention of the
intracellular lipid content in primary human
HSCs ex vivo
To further confirm the role of PNPLA3 in the retinol metabolism
of HSCs, we isolated human HSCs from surgical samples of pa-
tients homozygous for the PNPLA3 wild type (n¼ 3) and the mu-
tant allele (n¼ 2). We examined the effect of the mutation on
intracellular neutral lipid content after incubation of these pri-
mary human HSCs with retinol and palmitic acid for 24 h fol-
lowed by retinol depletion in retinol-free medium for 24 h.
Consistently with the LX-2 cell model, we observed that wild
type cells had lower intracellular neutral lipid content than the
I148M mutant cells (Fig. 3D and E).
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PNPLA3 148I wild type but not 148Mmutant promotes
reduced retinol-mediated secretion of MMP2, TIMP1
and TIMP2
To examine the effect of PNPLA3 wild type and mutant protein
on factors involved in fibrosis, we examined the intracellular
protein levels of several proteins belonging to different families.
Retinoids (including retinol) regulate metabolic pathways
through binding to nuclear receptors and are involved in fibrosis
(21,22), and therefore we examined cells in the presence of
retinol. Specifically, we incubated LX-2 cells with retinol and
palmitic acid for 24 h followed by retinol depletion in the reti-
nol-free medium for 24 h. Then, we tested for differences in in-
tracellular markers of cell activation (alpha smooth muscle
actin (a-SMA) and TGF-b receptor) and of extracellular matrix
formation and remodelling (metalloproteinases (MMPs), tissue
inhibitors of metalloproteinase (TIMPs) and collagen I) between
cells expressing the wild type or the mutant protein. We did not
observe any difference in intracellular protein levels between
cells overexpressing the PNPLA3 148I wild type or the 148M
mutant protein (Supplementary Material, Fig. S4A). Next, we ex-
amined the effect of the wild type and mutant protein overex-
pression on extracellular level of proteins involved in the
matrix formation (collagen I) and remodelling (MMPs and
TIMPs) after 24 h incubation with retinol and palmitic acid fol-
lowed by retinol depletion in retinol free medium for 24 h.
Concentrated medium (10X) from the cells overexpressing the
PNPLA3 148I wild type but not the 148M mutant protein and in-
cubated with retinol and palmitic acid had lower levels of
MMP2, TIMP1 and TIMP2 (Fig. 4A).
To confirm our results, we examined the levels of intracel-
lular markers of cell activation (a-SMA and TGF-b receptor)
and of extracellular levels of proteins involved in the matrix
formation (collagen I) and remodelling (MMPs and TIMPs) in a
time-dependent manner. Specifically, we examined intracellu-
lar markers and extracellular proteins after: a) 24 h incubation
Figure 2. PNPLA3 mediates the TGF-b-induced reduction in lipid droplet con-
tent in human pHSCs. (A) Intracellular neutral lipid content visualized by
ORO staining in pHSCs incubated with retinol and palmitic acid for 24 h and
then in medium without retinol-palmitic acid for the indicated times without
TGF-b (upper panel), with TGF-b 10 ng/ml (middle panel) and with TGF-b
10 ng/ml plus PNPLA3 siRNA (lower panel). (B) Intracellular ORO-stained area
of pHSCs without TGF-b, with TGF-b and with TGF-b plus PNPLA3 siRNA
quantified by BioPix. (C) Western blotting analysis of PNPLA3 expression
in pHSCs without TGF-b, with TGF-b and with TGF-b plus PNPLA3 siRNA
after 24 h.
Figure 1. PNPLA3 is upregulated by TGF-b and not by PDGF in primary hepatic stellate cells (pHSCs). Western blotting analysis of PNPLA3 expression in primary HSCs
incubated with (A) TGF-b (10 ng/ml) or (B) PDGF (10 ng/ml) for 0, 4, 8 and 24 h. The intensity of the western blotting bands was measured by Image Lab Software
(Bio-Rad) and expressed as relative density. The value obtained at 0 h was assigned as 1.
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with retinol and palmitic acid followed by retinol depletion in
retinol free medium for 12 h (Supplementary Material, Fig.
S5A); b) 48 h incubation with retinol and palmitic acid fol-
lowed by retinol depletion in retinol-free medium for 24 h
(Supplementary Material, Fig. S5B). Consistently, we obtained
similar results as in the experiment shown in Fig. 4 indicating
that the differences observed are PNPLA3 mutation and not
time dependent.
To test whether the release of retinol metabolites was re-
sponsible for the reduction in the secretion of MMP2, TIMP1 and
TIMP2, we examined the levels of these secreted proteins in the
medium of LX-2 cells overexpressing the wild type and the mu-
tant protein in the absence of retinol and palmitic acid. We did
not observe any difference in the intracellular (Supplementary
Material, Fig. S4B) or extracellular protein levels (Fig. 4B) of any
of the other markers examined.
To further examine the role of retinoids on MMP2, TIMP1
and TIMP2 secretion, we incubated cells overexpressing
the PNPLA3 wild type protein with retinol, palmitic acid and
increasing concentrations of liarozole hydrochloride, a potent
inhibitor of intracellular retinol metabolism. We observed a
dose-dependent increase in MMP2, TIMP1 and TIMP2 after
incubation with liarozole hydrochloride (Fig. 5A). To further
confirm the role of retinoids on changes of MMP2, TIMP1
and TIMP2 secretion, we examined the extracellular protein
levels of LX-2 cells overexpressing the PNPLA3 148M mutant
protein after incubation with increasing amount of all trans
retinoic acid (ATRA), a potent retinoid acid and X receptor
(RAR and RXR) agonist. We observed a dose-dependent re-
duction in extracellular protein levels of MMP2, TIMP1 and
TIMP2 in cells overexpressing the PNPLA3 148M mutant pro-
tein (Fig. 5B).
PNPLA3 is present in non-parenchymal hepatic sinusoi-
dal cells
To examine the role of PNPLA3 wild type and mutant protein in
human liver with steatosis, we used immunohistochemistry to
assess the distribution of PNPLA3 in different liver cell types in
hepatic specimens from patients homozygous for the wild type
or mutant allele. PNPLA3 was present at higher levels in non-
parenchymal sinusoidal cells of patients homozygous for the
mutant allele (Fig. 6A–C).
We finally examined the distribution of PNPLA3 in hepatic
specimens from individuals with advanced liver disease and
could not detect the protein in fibrotic strands (Fig. 6D).
Discussion
In this study, we examined the effect of the PNPLA3 protein and
its I148M variant in HSC activation and the acquisition of the
fibrogenic phenotype. We show that PNPLA3 is induced by TGF-
b and that the PNPLA3 I148M mutation impairs retinol-
palmitate release from primary human HSCs ex vivo. Moreover,
upregulation of the PNPLA3 wild type but not the mutant pro-
tein results in reduced extracellular levels of proteins involved
in fibrosis.
TGF-b is a potent inducer of HSC transactivation and fibro-
genesis (23) whereas PDGF induces cell proliferation (24). We
showed that TGF-b but not PDGF induced an upregulation of in-
tracellular PNPLA3 levels in primary human HSCs, indicating
the specificity of TGF-b in upregulating PNPLA3 levels. Similar
to our previous results showing that upregulation of PNPLA3 by
insulin induces the release of retinol from intracellular lipid
droplets in human HSCs (12), here we showed that TGF-b
Figure 3. Stable overexpression of PNPLA3 wild type (148I) but not mutant (148M) reduces intracellular lipid content in immortalized human hepatic stellate cells (LX-
2). (A) Lipid droplets visualized by ORO-staining in LX-2 cells stably expressing human V5-tagged 148I or 148M PNPLA3 and incubated with retinol (10 mM) and palmitic
acid (100 mM) for 48 h. Empty vector (EV) was used as negative control. (B) ORO-stained area quantified by BioPix. (C) Immunoblot showing transfection efficiency.
(D) Freshly isolated primary hHSCs, at third passage after isolation, were pre-treated with 300 mM palmitic acid and 10 mM retinol for 24 h and then incubated with qui-
escence medium (DMEM 0.5% FBS; wash-out) to evaluate their ability to release lipid droplets. Lipid droplets were visualized by ORO staining, and (E) ORO positive
(þve) area were quantified by ImageJ. Original magnification: 400X. n¼3 I148I PNPLA3 hHSCs and n¼ 2 M148M PNPLA3 hHSCs; * P<0.05 compared to I148I genotype.
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induced a PNPLA3-mediated reduction in intracellular lipid
droplets. These data suggest that PNPLA3 is upregulated during
the process of HSC activation by fibrogenic stimuli.
To investigate the impact of PNPLA3 upregulation of the
I148M mutation on the fibrogenic phenotype of HSCs, we gener-
ated a stable cell line of immortalized human HSCs overex-
pressing the wild type and the mutant protein. First, we
examined intra and extracellular level of proteins involved in fi-
brosis in cells cultured with retinol. To confirm our results, we
examined the effect of the PNPLA3 wild type and mutant pro-
tein on primary HSCs isolated from humans who were homozy-
gous for either of the two genotypes. Cells expressing the
PNPLA3 148M had higher intracellular neutral lipid content.
This is the first demonstration that the PNPLA3 I148M mutation
impairs retinol-palmitate release ex vivo from primary human
HSCs. These data are consistent with previous data showing
lower circulating free retinoids and higher retinoid levels in the
liver in carriers of the PNPLA3 148M mutation (25,26).
Earlier results from both experimental models and human
samples suggest that changes in expression of matrix metallo-
proteinases (MMPs) and their tissue inhibitors (TIMPs) contribute
to fibrosis remodelling (27). Specifically MMP2 expression in-
creases in experimental fibrosis models and in human chronic
liver disease (28–32). Moreover TIMP1 and TIMP2 expression in-
creases dramatically in activated HSCs (33) and in the liver of rats
treated with CCl4, a compound used to induce fibrosis (34). Here
we showed that stable overexpression of the PNPLA3 wild type
but not the mutant protein induced a reduction in extracellular
Figure 4. PNPLA3 wild type but not PNPLA3 148M mutant overexpression induces a reduction in the secretion of MMP2, TIMP1 and TIMP2. Concentrated (10X) medium
fractions of LX-2 stable cell lines expressing empty vector (EV), PNPLA3 WT or PNPLA3 148 M incubated with (A) regular medium plus retinol 10 mM and palmitic acid
100 mM for 24 h and then in retinol-palmitic acid free medium without FBS for 24 h, and (B) regular medium without retinol and palmitic acid for 24 h and then in me-
dium without FBS for 24 h. Calnexin was used as loading control. MMP14: matrix metalloproteinase14; MMP2: matrix metallopeptidase 2; MMP9: matrix metallopepti-
dase 9; TIMP1: tissue inhibitor of metalloproteinase 1; TIMP2: tissue inhibitor of metalloproteinase 2; COL I: collagen Ia1.
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levels of MMP2, TIMP1 and TIMP2 in the medium of HSCs incu-
bated with retinol and palmitic acid. Our results suggest that
upregulation of the PNPLA3 wild type protein prevents the re-
lease of proteins that increase liver fibrosis. The mutant protein
is a loss of function variant and therefore the protective effect of
PNPLA3 is hampered in HSCs carrying this mutation.
To investigate the mechanisms underlying the effect of
PNPLA3 on the fibrogenic phenotype of HSCs we incubated cells
without retinol and palmitic acid. We observed no differences
in the extracellular protein levels of MMP2, TIMP1 and TIMP2 be-
tween the cells overexpressing the 148I wild type or the 148M
mutant protein in the medium of cells incubated without reti-
nol. These results suggest that the PNPLA3 effect on these
markers is mediated by retinoids. To test this hypothesis, we in-
cubated cells overexpressing the wild type with increasing
amount of liarozole, a potent inhibitor of retinol metabolism.
Increasing concentrations of liarozole induced a progressive in-
crease in extracellular levels of MMP2, TIMP1 and TIMP2. Vice
Figure 5. The PNPLA3 induced reduction in MMP2, TIMP1 and TIMP2 secretion is due to retinoids. (A) Liarozole hydrochloride induces an increase in the MMP2, TIMP1
and TIMP2 secretion in LX-2 cells stably overexpressing wild type PNPLA3. Left panels: Western blotting analysis of LX-2 cells stably over-expressing PNPLA3 148I in-
cubated with regular medium plus retinol 10 mM, palmitic acid 100 mM and increasing Liarozole Hydrochloride (10 mM, 50 mM and 100 mM) for 24 h and then in retinol-
palmitic acid free medium without FBS for 24 h. Right Panels: relative quantification of western blotting bands of the left panels. (B) All trans retinoic acid (ATRA)
induces a reduction in the secretion of MMP2, TIMP1 and TIMP2 in LX-2 cells stably over-expressing PNPLA3 148M mutant protein. Right Panels: western blotting of
MMP2, TIMP1 and TIMP2 in LX-2 cells stably over-expressing PNPLA3 148M incubated with regular medium plus retinol 10 mM, palmitic acid 100 mM and increasing
ATRA (30 mM, 60 mM and 100 mM) for 24 h and then in retinol-palmitic acid free medium without FBS for 24 h. Right panels: relative quantification of western blotting
band in the left panels. Albumin was used as loading control. MMP2: matrix metallopeptidase 2; TIMP1: tissue inhibitor of metalloproteinase 1; TIMP2: tissue inhibitor
of metalloproteinase 2.
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versa, incubation of the cells overexpressing the mutant protein
with increasing amount of ATRA, a potent RAR/RXR agonist, in-
duced a progressive reduction of extracellular levels of these en-
zymes. Thus, we recapitulated the wild type phenotype in cells
carrying the mutant by incubating with a retinoid agonist, and
the mutant phenotype in cells carrying the wild type protein by
incubating with a retinoid antagonist. These results show that,
in our model, the PNPLA3-mediated effect on proteins involved
in fibrosis remodelling is mediated by retinoids.
We have previously shown that PNPLA3 is expressed and syn-
thetized in hepatocytes, and that higher expression of the 148M
mutant protein is associated with increased risk of liver damage
related to nonalcoholic fatty liver disease, likely due to impair-
ment of lipid droplet remodelling (12,35). Here, we showed that
PNPLA3 was present at higher levels in non-parenchymal sinu-
soidal cells from humans who were homozygous for the mutant
allele compared with the wild type PNPLA3. In contrast, PNPLA3
was not detectable in other cells of fibrotic strands during ad-
vanced human liver disease. These findings are consistent with
the hypothesis that PNPLA3 mutant protein induces liver fibrosis
by acting in HSCs and not in other fibrogenic cells involved in
later stages of fibrosis. The detailed characterization of non-
parenchymal PNPLA3-positive cells in human liver samples of
healthy individuals and patients with liver diseases will require
further studies evaluating by immunofluorescence the co-
staining of PNPLA3 with a-SMA and other cell markers, which
was not possible in our paraffin-embedded tissues.
It is generally accepted that retinol loss occurs after HSC acti-
vation, but it is not known whether this loss triggers, facilitates
or increases the HSC activation. Our data suggest that retinol loss
does not worsen the fibrogenic phenotype of HSCs. In fact,
PNPLA3-mediated retinol release may rather be a protective
mechanism against fibrosis involving regulation of HSC activa-
tion and extracellular matrix remodelling. The PNPLA3 I148M is a
loss of function variant determining a reduced rate in the release
of retinoids from lipid droplets impairing this feedback mecha-
nism. On the basis of our results, we propose the following
model: upon HSC activation by fibrogenic stimuli, upregulation of
the wild type PNPLA3 protein counteracts fibrosis by reducing the
release of enzymes that facilitate fibrosis in a process that is me-
diated by retinoids (Fig. 7). In carriers of the loss of function
PNPLA3 mutant, the release of retinoids from lipid droplets is re-
duced, and thus the protection from fibrosis is lost (Fig. 7).
The main limitation of this work is that it does not account
for the cross talk between different liver resident cell types.
Further in vitro and in vivo studies are required to understand
the mechanism linking PNPLA3 with liver fibrosis.
In conclusion, we show a role for PNPLA3 in HSCs activation
in response to fibrogenic stimuli. Moreover, our results indicate
that PNPLA3-mediated retinol release may have a role in pro-
tecting against liver fibrosis by inducing the secretion of a spe-
cific signature of proteins that are involved in extracellular
matrix remodelling.
Materials and Methods
Cell culture
Primary human hepatic stellate cells (pHSCs) cryopreserved
after purification from human liver were purchased from 3H
Figure 6. PNPLA3 is present in non-parenchymal hepatic sinusoidal cells. Immunohistochemistry (IHC) analysis of PNPLA3 was performed on liver specimens obtained
from NAFLD patients carriers of the two different PNPLA3 genotypes (I148I panel A, M148M panel B). Non parenchymal cells, most likely HSCs localized in sinusoidal
spaces, are indicated by the arrows. (C) Percentage of PNPLA3 positive cells, manually counted with ImageJ. The expression of PNPLA3 is higher in liver biopsies from
M148M patients compared to I148I. (D) Liver sample characterized by fibrotic areas showing PNPLA3 cytoplasmic positivity in hepatocytes, but not in cells localized be-
tween fibrotic septa. Nuclei were contrasted by hematoxylin staining. Original magnification: 200X. n¼ 4 I148I PNPLA3 patients and n¼3 M148M PNPLA3 patients;
*P<0.05 compared to I148I genotype.
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Biomedical. After thawing, cells were plated in T-75 flasks
coated with poly-L-lysine and grown in SteCM medium contain-
ing foetal bovine serum (FBS) 2% for 5 passages. Then, retinol
and palmitic acid were added to restore the quiescence state
(36). Immortalized human HSCs (LX-2) were kindly provided by
Professor Scott L. Friedman (Mount Sinai School of Medicine)
(33). LX-2 cells were grown in high glucose DMEM containing
FBS 10% in T-75 flasks. Cells were seeded in 24-well plates with
cover slips for Oil Red O (ORO) staining or in 6-well plates and T-
75 flasks for immunoblot. pHSCs were seeded in 6-well plates
and 24-well plates with cover slips for 24 h. Then the cells were
incubated with TGF-b 10 ng/ml (SigmaAldrich) or PDGF 10 ng/ml
(SigmaAldrich) for 0, 4, 8 and 24 h. Western blotting was per-
formed to assess the PNPLA3 levels and ORO staining was per-
formed to measure intracellular lipid droplet content.
PNPLA3 knockdown
pHSCs were transfected with PNPLA3 small interfering RNA
(siRNA) or negative control (scramble) siRNA (Ambion-Life
Technologies by Thermo Fisher Scientific, Rockford, IL) with
TurboFect Transfection Reagent (Thermo Scientific) according
to the manufacturer’s instructions. The cells were transfected
with 25 nM siRNA oligos in serum-free medium.
Stable cell line generation
Expression plasmids pcDNA 3.1 (30 mg for the T-75 plate) with a V5
fusion tag, containing the human 148I wild type or 148M mutant
PNPLA3 cDNA were used to transfect LX-2 cells using TurboFect
reagent according to the manufacturer’s protocol. An empty vector
was used as a negative control. Forty-eight hours after transient
transfection, LX-2 cells were treated with 4 mg/ml of geneticin-
G418 (Life Technologies), to select resistant cells. After 15 days, six
single colonies per each genotype were selected and expanded. An
empty vector was used as a negative control. Western blotting
was performed to determine PNPLA3 expression levels. A single
cell clone for each genotype was used for all the experiments.
Transfection efficiency was assessed using an anti-V5 antibody.
LX-2 cells stably expressing human V5-tagged 148I or 148M
PNPLA3 were incubated with albumin (3 mg/ml), retinol (10 mM)
and palmitic acid (100 mM) for: (a) 48 h; (b) 48 h plus 24 h with reg-
ular medium; (c) 24 h; (d) 24 h plus 12 h with regular medium; (e)
24 h plus 24 h with regular medium. ORO staining was per-
formed for each time point.
Next, LX-2 stably expressing human V5-tagged 148I or 148M
PNPLA3 were incubated with albumin (3 mg/ml), retinol (10 mM)
and palmitic acid (100 mM) for: (a) 24 h plus 24 h with regular me-
dium without FBS; (b) 24 h plus 12 h with regular medium with-
out FBS; (c) 48 h plus 24 h with regular medium without FBS; (d)
regular medium without retinol and palmitic acid for 24 h and
then in regular medium without FBS for 24 h. Medium fractions
and cells were collected and analysed by western blotting after
each time point.
LX-2 cells stably expressing PNPLA3 148M were also incubated
with albumin (3 mg/ml), retinol (10 mM), palmitic acid (100 mM)
plus all trans retinoic acid (ATRA) (30 mM, 60 mM, 100 mM) for 24 h
and then with regular medium without FBS for 24 h. Medium
fractions were collected and analysed by western blotting.
LX-2 cells stably expressing PNPLA3 148I wild type were incu-
bated with albumin (3 mg/ml), retinol (10 mM), palmitic acid (100
mM) plus liarozole hydrochloride (10 mM, 50 mM, 100 mM) for 24 h
and then with regular medium without FBS for 24 h. Medium
fractions were collected and analysed by western blotting.
Human HSC isolation
Human HSCs were isolated from non-neoplastic human liver
tissue obtained from explanted or resected livers of patients. All
samples were negative for hepatitis B virus surface antigen
(HBsAg) and for hepatitis C virus (HCV)-RNA. Samples from do-
nors with variable steatosis and fibrosis grade and with no age
restriction were included in the study. Informed written con-
sent of each patient was obtained, according to legal and ethical
rules established by the Ethics Committee of the Fondazione
IRCCS Ca Granda, which has already approved the protocol.
Liver tissues were stored in a Celsior preservation solution for a
maximum of 8 h from the explantation at 4 C.
Figure 7. Putative model of PNPLA3 in hepatic stellate cells. (A) PNPLA3 overexpression promotes release of retinoids which down-regulates in the nucleus the expres-
sion of MMP2, TIMP1, TIMP2. (B) When the 148M mutation occurs, the retinyl-palmitate lipase activity of PNPLA3 is lost, leading to retinol retention and subsequent in-
creased secretion of pro-fibrotic factors and extracellular matrix deposition. LD: Lipid droplet; N: nucleus; MMP2: matrix metallopeptidase 2; TIMP1: tissue inhibitor of
metalloproteinase 1; TIMP2: tissue inhibitor of metalloproteinase 2.
5219Human Molecular Genetics, 2016, Vol. 25, No. 23 |
Human HSCs were isolated by a multi-step ethylene glycol
tetra-acetic acid (EGTA)/collagenase-pronase perfusion tech-
nique, through adequate micro cannulation of small blood ves-
sels to ensure efficient perfusion of the tissue sample, followed
by centrifugation on a density gradient with Optiprep to isolate
human HSCs, taking advantage of their low density, as de-
scribed before in a murine model (37).
Human HSCs isolated were cultured on plastic for a few pas-
sages (37). Cells were grown in DMEM medium in T-75 flasks.
When confluent, cells were passaged using trypsin and seeded
at a ratio of 1:3. Experiments were performed at the third pas-
sage of culture. Three independent lots of freshly isolated hu-
man HSCs carrying 148I/I and two carrying 148M/M PNPLA3
genotype, were used for experiments. Briefly, 4 h after isolation,
primary human HSCs were treated with 10 mM retinol and 300
mM palmitic acid (Sigma Aldrich, St Louis, MO) for 24 h and then
incubated with quiescence medium (DMEM 0.5% FBS) (wash-
out). Lipid droplet content was visualized by ORO staining (12)
and ORO positive area was quantified by ImageJ software in 10
random micrographs (magnification 200x) by calculating the
ORO positive area as percentage of pixels above the threshold
value with respect to the total pixels per area.
Oil red O (ORO) staining
The total area of ORO-stained lipid droplets was determined as
described previously (38). Pictures were obtained using Axio KS
400 Imaging System and AxioVision 4.8 Software (Zeiss) at 100X
magnification. ORO-stained area was quantified by BioPix or
ImageJ software for the in vitro and ex vivo model respectively.
Immunoblot analysis
Cells were lysed in M-PER Mammalian Protein Extraction
Reagent (Pierce, Thermo Fisher Scientific) containing complete
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
Medium fractions were collected and concentrated 10X using
VIVASPIN tubes (MWCO 10KDa). Immunoblot analysis was per-
formed according to standard procedures. Bands were visual-
ized using a Chemidoc XRS System and Image Lab Software
(Bio-Rad).
The following antibodies were used: mouse anti-V5 (P/N 46-
0705) by Invitrogen, rabbit anti-PNPLA3 (AV48936), rabbit anti-
calnexin (C4731), rabbit anti-MMP14 (M5808), rabbit anti-MMP2
(HPA001939), mouse anti-MMP9 (SAB140274), mouse anti-TIMP2
(WH0007077M1), rabbit anti-collagen I (HPA011795), mouse anti-
a-SMA (A5228), mouse anti-albumin (A6684) by Sigma-Aldrich,
rabbit anti-TIMP1 (AB81282) and rabbit anti-TGF-b receptor
(AB138248) by Abcam.
Statistical analysis
Data from in vitro experiments were analysed using Mann-
Whitney non-parametric test. P-values of<0.05 were considered
significant and indicated as * in figures. Bar graphs in figures
show mean6SD of three experiments unless otherwise
specified.
Immunohistochemistry
Liver biopsies were fixed in 10% PBS buffered formalin and then
embedded in paraffin within 24 h of formalin fixation. We per-
formed immunohistochemical analysis to evaluate PNPLA3
expression in liver tissues from patients homozygous for the
two different genotypes (148I, 148M), as previously described
(35).
Briefly, de-paraffinated sections were re-hydrated in alcohol
and endogenous peroxidase activity was blocked with metha-
nol/10% hydrogen peroxide. After unmasking with the proper
antigen retrieval and treating with blocking solutions, the slides
were incubated overnight at 4 C with PNPLA3 antibody (Abcam,
ab188856) 1:75. After rinsing, slides were incubated with the ap-
propriate horseradish peroxidase-conjugated secondary anti-
body and developed with 3-3-diaminobenzidine (DAB). The
slides were analysed with the Leica DMD108 microscope (Leica)
connected to a digital camera (Leica). PNPLA3 quantification
was performed in 10 random non-overlapping fields per slide
(200X magnification) by manually counting the number of cells
localized in sinusoidal spaces with the software ImageJ. The re-
sults are expressed as percentage of positive cells localized in si-
nusoidal space per field.
Supplementary Material
Supplementary Material is available at HMG online.
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